anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound of formulaI(A is CH3S-CH2-CH<). EXAMPLE:Boc-L-Tyr-GlY-GlY-L-Phe-L-Leu-al. USE:A drug that can be expected as an analgesic or its synthetic intermediate. It has a strong analgesic activity. PREPARATION:A peptide alcohol of formula II is made to react with a sulfur trioxide complex in DMSO in the presence of triethylamine to give the compound of formulaI. The amounts of triethylamine and sulfur tiroxide used in the above reaction is sufficiently 2.5 equivalents, however, about 3 equivalents respectively. Examples of sulfur trioxide complexe are derived from sulfur trioxide and pyridine, dioxane or DMF. In the formula, Boc represents tertiary butyl carbonyl; Tyr, the residue of tyrosine; Gly, the residue of glycine and Phe, the residue of phenylalanine.
In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on motoneuronal activation in healthy adults, which typically decreases with age. The investigators will also test whether WB-EMS Exercise will improve measures of physical function. The intervention consists of WB-EMS Exercise twice a week for four weeks. The investigators will use decomposition electromyography, interpolated twitch technique, and clinical measures to assess pre- and post-treatment motoneuronal activation and physical functioning. Correlation matrices will be performed associating the measures of motoneuronal activation to the measures of physical function (pre-intervention values, post-intervention values, and change values). At the conclusion of the study, expected outcomes include that whole-body electrical muscle stimulation combined with physical exercise (WB-EMS Exercise) could bypass the problem of insufficient motoneuronal activation to improve exercise effect in older adults. This project represents early work to uncover motoneuronal mechanisms of WB-EMS Exercise in older adults. An intervention that combines voluntary and involuntary activation of motoneurons to enhance the effectiveness of exercise could have significant impact in maximizing the functional independence of an aging population.
The purpose of this study is to test the functions of dorsolateral prefrontal cortex in human motor learning. Dorsolateral prefrontal cortex (DLPFC) has been found to be involved in cognitive functions such as executive function, response selection, and working memory. Recent Findings hint potential involvement of dorsolateral prefrontal cortex in motor learning. Rare studies provided supporting evidence on its involvement and functions. This study aims to examine the functional roles of dorsolateral prefrontal cortex in human motor learning. By applying transcranial magnetic stimulation (TMS) or transcranial focused ultrasound (FUS), which is a technology to temporally alter brain state in the stimulation site, the investigators aim to find supporting evidence for the causal relationship between the targeted stimulation site and motor learning improvement or response selection.

Young healthy adults will be recruited and randomly assigned to one of four experimental groups. If randomized into one of the TMS groups, participants will learn to adapt to two visual rotations (20 and 60 degrees) when reaching for a virtual target, subjects will receive repetitive TMS (rTMS) stimulation over the targeted location, left DLPFC, or right DLPFC depending on the study group. How rTMS stimulation influencing the acquisition and retention of motor memory will be assessed based on group comparison of behavioral measures such as reaching accuracy. If randomized into the FUS group, participants will complete a flanker task to focuses on the assessment of response selection and inhibitory control.
Overweight and obesity are leading health problems. The study investigates the effect of a food ingredient from two different sources at two different doses on food intake and appetite markers over a 10 hour period. All participants reported to the laboratory first thing in the morning and remained in the laboratory until after their evening meal. A fixed breakfast was served but the participants were free to eat as much as they liked at lunch and dinner. Blood was taken at regular intervals during the day and assayed for glucose and several hormones related to appetite. Subjective measures of appetite were also collected over the 10 hour test session.
The invention relates to a protein fusing a new coronavirus subprotein and an IgG1-Fc region and application thereof in vaccine development. The fusion protein is formed by new coronavirus S1 subunit RBD protein shown as SEQ ID NO. 1, new coronavirus S1 subunit protein shown as SEQ ID NO. 5, membrane glycoprotein subunit protein shown as SEQ ID NO. 7 or nucleocapsid phosphoprotein subunit shown as SEQ ID NO. 8; linked to the IgG1-Fc region. The fusion protein can be used as immunogen to stimulate the production of antibody, and can kill virus in the first time of virus infection to protect human body from virus invasion.
Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit. The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit. The invention relates to a device and a corresponding method for treating surfaces (F) of metallic components (M), especially for treating the tracks of the cylinder ports (Z) of combustion engine blocks (M), by means of a laser beam (L). Said device comprises a deflecting lens system (14) for deflecting the laser beam from a direction extending in the longitudinal direction of the surface that is to be processed into a direction that deviates therefrom and is oriented towards the surface that is to be processed. In order to minimize, with simple means, the risk of the lens getting dirty prematurely in such a device or such a method, a translucent deflection unit (13, 113) is placed upstream of the deflecting lens system, said deflection unit (13, 113) being provided with penetration areas for the laser beam that are plane-parallel to each other and extend at an angle to the direction in which the laser beam hits the deflection unit.
The South African genetic screening services for breast cancer comprise targeted and comprehensive tests that screen for the presence of genetic alterations. Clinically, these variants determine the risk of disease development as well as treatment approaches best suited for carriers. The current targeted tests screen for seven pathogenic sequence variants, which are mainly common among Whites, a population that constitutes 9.1% of South Africa. However, these tests are offered to all patients despite consistent negative results observed among Blacks, Indians, and Mixed ancestry (known as Coloreds in South Africa). Consequently, Blacks, White, and Colored patients who potentially carry other variants receive unbefitting treatment, resulting in poor clinical response, recurrence, and high mortality. This review aimed to identify the presence and incidence of pathogenic variants in BRCA1/2 previously reported in all South African populations. We selected literature using a scoping review approach, from which we included eight articles and two reports. Overall, we identified 59 BRCA1 and 60 BRCA2 pathogenic sequence variants from a cohort of 5709 patients and unknown patients from 90 families. The most reported variant was BRCA2 c.7943delG, which was common in White and Colored patients. None of the seven common variants was reported in either Blacks or Indians, which demonstrates the urgency to tailor genetic tests which are optimal for all South African patients and present a range of variants which could serve as diagnostic targets for Black, Indian, and Colored patients.
Introduction. Cytotoxin-associated gene A (CagA) from Helicobacter pylori is highly related to chronic gastritis. Tyrosine phosphorylation of Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs from CagA determines the pathogenicity of H. pylori.Gap statement. The precise amino acid variations surrounding the EPIYA motifs and their correlation with clinical outcomes have been poorly explored.Aim. The purpose of this study was to examine the CagA 3' region polymorphism of H. pylori and its association with chronic gastritis in the Chinese population.Method. A total of 86 cagA-positive H. pylori strains were isolated from patients with chronic gastritis in two different hospitals in Beijing, PR China. Genomic DNA was extracted commercial kits, and the cagA 3' variable region of H. pylori was amplified by polymerase chain reaction (PCR). The PCR products were sequenced and analysed using the CLC Sequence Viewer, BioEdit, and WebLogo 3.Results. Two hundred and fifty-nine EPIYA motifs were identified from cagA-positive H. pylori strains. Notably, EPIYA-B exhibited a higher frequency of variation in comparison to EPIYA-A, EPIYA-C, and EPIYA-D. The prevalent sequences for East-Asian-type CagA were QVNK and TIDF, while KVNK and TIDD were most commonly observed for Western-type CagA. The CRPIA motifs of East-Asian-type CagA and Western-type CagA varied at positions 4, 6, 7, 8, and 10. CagA-ABD (73.2%) was the most prevalent type, followed by CagA-ABC (18.6%) and CagA-AB (3.4%). The ratio of CagA-ABD was observed to be higher in cases of chronic non-atrophic gastritis with erosive (NAGE) or chronic atrophic gastritis (AG) compared to chronic non-atrophic gastritis (NAG), and the difference was found to be statistically significant (χ2=59.000/64.000, P<0.001).Conclusions. The EPIYA segments of Western-type CagA and East-Asian-type CagA differ significantly and the presence of CagA-ABD may be associated with severe chronic gastritis from this study.
A hair care prepn. contg. elastase was prepd. and it promoted an outgrowth of new hairs, nourished outgrown hairs, stimulated scalp metabolism, and prevented depilation.  Thus, animal test showed no abnormal or pathogenic findings when elastase was orally applied, and no particular toxicities against the scalp when dissolved elastase topically applied.  A hair lotion was prepd. by contg. elastase, silicone oil, polyethylene-hardened castor oil, phosphate buffer and EtOH.
Intimate partner violence (IPV)-exposed Black women are often forced to choose between relationship safety and HIV prevention; thus, trauma-, gender-, culturally-responsive HIV prevention interventions are needed for this key priority population. Pre-exposure prophylaxis (PrEP) may be a viable partner-independent option for IPV-exposed Black women, but no study has identified an evidence-based strategy to promote and increase PrEP uptake among this population, specifically IPV-exposed Black women in the South. Guided by the Consolidated Framework for Implementation Research (CFIR), the proposed research aims to adapt, implement and evaluate self- and advocate-administered versions of a PrEP decision aid in a domestic violence agency in Baltimore in order to increase PrEP uptake among Black women in Ending the HIV Epidemic (EtHE) priority areas, address trauma as a barrier to PrEP uptake, and ultimately combat racial disparities in women's HIV cases.

Therefore, this Type II hybrid effectiveness-implementation study seeks to adapt an existing PrEP decision aid to IPV-exposed Black women seeking domestic violence (DV) services in Baltimore, an EtHE priority state. Self- and advocate-administered versions of the PrEP decision aid will be implemented and the aid will be evaluated using a three-arm randomized trial. The Consolidated Framework for Implementation Research (CFIR) will guide this research. A formative evaluation using qualitative interviews with IPV-exposed Black women (N=10) and DV advocates (N=20) was conducted to adapt the PrEP decision aid. Next, the decision aid will be implemented in a DV agency and 90 IPV-exposed Black women will be randomized to either the self- or advocate-administered versions of the aid, or the control intervention, in order to compare feasibility, acceptability and preliminary effectiveness with baseline, 1-, 3-, and 6-month surveys. Focus groups with DV advocates and participants will assess for implementation process outcomes. This study will: provide support for a PrEP decision aid that addresses HIV prevention for IPV-exposed Black women; use implementation science to increase PrEP uptake; include DV agencies in intervention development and implementation; and improve understanding of PrEP scale-up by addressing implementation factors in settings that serve IPV-exposed Black women.
The deposition of the extracellular matrix, especially collagen, and the elevated expression levels of reactive oxygen species, including H2O2, are the main features of fibrosis. Fibrosis can occur in many tissues, such as tumor and liver tissues. The deposition of collagen in the location of lesions not only leads to immunological rejection and supports liver fibrosis and tumor progression, but also provides unique physiological signals with the progression of fibrosis and tumor. However, at present, the detection of fibrosis, especially real time detection, is greatly difficult, making it important to develop noninvasive probes for the dynamic monitoring of fibrosis progression. Herein, we propose a H2O2 responsive macromolecular probe for collagen imaging with high sensitivity and specificity. This probe consists of a collagen-targeting peptide and a H2O2-sensitive and near-infrared (NIR)-emitting macromolecular optical probe, which could effectively bind to collagen both in vitro and in vivo in the region of tumor or fibrotic liver tissues, allowing for high sensitivity and noninvasive visualization of fibrotic tissues and real time monitoring of collagen degradation after anti-fibrotic drug treatment.
<P>PROBLEM TO BE SOLVED: To provide a method for utilizing a gene specific to various types of cancer.  <P>SOLUTION: Hybridization is carried out on slides obtained by preparing RNAs from 38 cell strains derived from lung cancer, 3 normal fibroblast strains, 43 clinical specimens of the lung cancer and 6 normal pulmonary tissues, labeling them with a fluorescent material, and immobilizing 7685 kinds of gene fragments thereon. Usual hierarchical clustering is applied thereto, and the whole cell strains and clinical specimens are separated to each different cluster. The gene expression profile influenced by each type of diseases is considered to be obtained by removing genes commonly highly expressing or lowly expressing in the cultured cell strains or the clinical specimens from the analysis, and a filtering method enabling the removal is newly considered and carried out. As a result, the gene exhibiting disease type-specific expression profile can be identified. The gene is considered to be useful in diagnosis and therapy of each type of the cancer.  <P>COPYRIGHT: (C)2004,JPO
The invention discloses a preparation method of a novel genetically recombinant pure protein antigen and relates to the technical field of protection of hemagglutinin viruses and development of detection reagents. The preparation process comprises the following steps: I, gene recombinant expression of a hemagglutinin H7 antigen; II, preparation of the hemagglutinin H7 antigen; III, application of the hemagglutinin pure protein to animals/human bodies; and IV, application of the high purity hemagglutinin H7 antigen to detecting hemagglutinin H7-containing viruses. The novel genetically recombinant pure protein antigen has the characteristics of high purity and good antigenicity, and does not exist in form of granules and not only does not contain any genetic materials such as RNA (Ribonucleic Acid), but also does not contain other protein impurities. The novel genetically recombinant pure protein antigen can be used for preparing a high specific antibody for H7N9. Because of the protein characteristic of the H7 antigen, the chromatographic method can be used for purifying a single antigen, and the purity of SEC-HPCL (Size Exclusion Chromatography-High Performance Liquid Chromatography) is higher than 90%. The high purity H7 antigen and the highly specific H7N9 antibody can be used for developing diagnostic reagents for diagnosing H7N9 avian influenza.
Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
The study plans to recruit 3 participants with Parkinson's disease . Using stereotactic technology, hAESCs will be accurately transplanted into the lateral ventricle. Therapeutic effectiveness and safety of hAESCs on PD will be evaluated. hAESCs are derived from placental amnion donated after cesarean section in healthy women. hAESCs is developed from the epiblast as early as 8 days after fertilization, recent reports indicate that hAESCs have some characteristics of neural stem cell. These cells are able to differentiate into dopaminergic neurons and secrete dopamine and various neurotrophic factors. These HAESCs could be seen as one of the best potential stem cell source for treating Parkinson's disease.
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
The present invention relates to an aminochlorodipin and irbesartan compound preparation and application. A novel blood pressure reduction compound preparation disclosed by the present invention is a medical composition prepared from aminochlorodipin and irbesartan which are used as active ingredients. The preferable weight ratio of the aminochlorodipin to the irbesartan is 1:10 to 50. The dosage of the compound preparation is obviously lower than that of each medical ingredient which is singly used. The effect of blood pressure reduction can be obviously strengthened, and the duration time of blood pressure reduction can be prolonged. The compound preparation is especially suitable for hypertension patients who simultaneously have angiocarpy reconstruction. Simultaneously, the compound preparation is also suitable for treatment of patients who have renal hypertension, hypertension with harm to renal functions or harm to renal functions of diabetes.
This is multicenter prospective cohort evaluation of the implementation of a cryptococcal antigen (CrAg) screening program in Vietnam. HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA) and followed up for 12 months with clinical assessments and the collection of routine and supplemental survey data. Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole. Those with symptoms of CNS disease will be treated according to national guidelines. Survival, retention in care, and other clinical outcomes will be documented for patients who test CrAg-positive and are treated with fluconazole and those who test CrAg-negative.
Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
BACKGROUND AND AIMS: Manipulation of colorectal polyps by biopsy, incomplete resection, or tattoo placement under the lesion has been shown to cause submucosal fibrosis and associated inferior outcomes. The effect of delays between index manipulation and definitive resection on the incidence of fibrosis is unknown.
METHODS: Patients undergoing EMR of previously manipulated colorectal polyps ≥10 mm from 2016 to 2021 at a tertiary referral center were included. Time from index manipulation to definitive resection and the presence of fibrosis were noted. The effects of fibrosis on EMR outcomes were assessed.
RESULTS: Among 221 previously manipulated lesions (180 biopsy, 23 incomplete/failed resection, 1 tattoo under lesion, 17 multiple types of manipulation), 51 (23%) demonstrated fibrosis. Fibrotic lesions were found to have been resected significantly later than nonfibrotic lesions (76 vs 61 days; P = .014). In a multivariate analysis controlling for other predictors of fibrosis, each 2-week delay was associated with a 14% increase in the odds of fibrosis. Fibrotic lesions had inferior outcomes with a lower en-bloc resection rate (8% vs 24%; P = .014) and longer procedure time (71 vs 52 minutes; P < .001). Adverse event and recurrence rates were similar between groups.
CONCLUSIONS: Delays in definitive resection of previously manipulated polyps are associated with an increased incidence of fibrosis with time and associated inferior outcomes. Manipulation should be discouraged, and if it occurs, prompt referral and scheduling for definitive resection should be prioritized.